First Quarter 2023 Financial Results and Business Update Conference Call

Aaron Berg
Interim CEO & President

Tom Reilly
CFO

May 3, 2023



AMARIN®

Forward Looking Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA®(VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, research and development, intellectual property and litigation matters, and other statements and beliefs that are forward-looking in nature and depend upon or refer to future events or conditions, including certain financial initiatives, metrics, and guidance.

These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the "Risk Factors" section in Amarin's most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

THIS PRESENTATION IS INTENDED FOR COMMUNICATION WITH INVESTORS AND NOT FOR DRUG PROMOTION.

Today’s Agenda

01

First Quarter 2023 Business Update
Aaron Berg, Interim President & CEO

02

First Quarter 2023 Financial Results
Tom Reilly, CFO

Looking Ahead to the Remainder of 2023
Aaron Berg, Interim President & CEO

01

FIRST QUARTER 2023 BUSINESS UPDATE

Aaron Berg, Interim President & CEO

New Amarin Board of Directors Focused on Shareholder Value


Patrice Bonfiglio


Paul Cohen, MD


Mark DiPaolo


Keith Horn


Odysseas Kostas, MD


Oliver O'Connor


Louis Sterling


Diane Sullivan

Our Near-Term Strategy is Simple

Maintain Profitability in US

Accelerate Activities in EU

Maximize Our CASH

Maintaining Market Share Through Continued Generic Competition

Two-Plus Years Into Generic Competition



Despite Generics, U.S. Business Has Maintained 57% Market Share

Amarin Plans to Manage US Profitability via Multiple Levers

Vascepa® (icosapent ethyl)

Maintain branded VASCEPA®

Further operating expense reductions

Ability to move to branded generic

Ability to launch an authorized generic

Amarin is focused on retaining leadership position and maximize the profitability of the US business

U.K. Formulary Process Began in October 2022

2021

JAN FEB MAR APR MAY JUN JUL AUG SEPT OCT NOV DEC

APRIL 8, 2021
MHRA Approves VAZKEPA for reducing the risk of cardiovascular events in statin treated eCVD with fasting TG > 1.7 mmol/l, LDL-C 1.04 - 2.60 mmol/l (>70 KOL endorsements)

JULY 2021
Amarin Completes VAZKEPA NICE Submission

2022

JAN FEB MAR APR MAY JUN JUL AUG SEPT OCT NOV DEC

JUNE 2022
Amarin UK Officially Operational , Key Account Managers in the field

JULY 2022
Amarin Receives Final NICE Guidance for VAZKEPA Reimbursement for statin treated eCVD with fasting TG > 1.7 mmol/l, LDL-C 1.04 - 2.60 mmol/l

JULY 2022
Amarin completes building UK Commercial team

OCT 2022
NICE funding availability

NOV 2022
NICE publishes new National Lipid Guidelines including TG testing & Vazkepa

Strong Initial Market Access Performance in the U.K.

Uptake from NICE TA Slide

Cumulative positive formulary inclusion from NICE TA



- 98/113 formularies (87%) > DS Nilemdo & Novartis' Leqvio
- 20/20 unlocked priority accounts = access to 52% eligible patient population
- 60% (59) have AI 100% (any HCP can Rx), 26% (25) have AI 65% (Specialists can Rx)

Priority Account	Eligible Patient Population	Availability Index
Cheshire & Merseyside ICB (Pan Mersey)	29,000	100
North East & North Cumbria ICB (County Durham)	28,597	100
Greater Manchester ICB (GMMMG)	27,366	100
North West London ICB (Chelsea and Westminster)	20,100	100
North East London ICB (Barts)	19,420	100
Northern Ireland	18,072	100
Kent and Medway ICB (East Kent, West Kent)	17,802	100
Hampshire & the Isle of Wight ICB	17,398	100
South East London ICB	17,263	65
Sussex ICB (East Sussex West Sussex)	16,320	100
West Yorkshire ICB (Leeds)	15,236	100
Birmingham & Solihull ICB	11,192	65
Nottingham & Nottinghamshire ICB	9,980	65
Derby & Derbyshire ICB	9,845	30
Bedfordshire, Luton & Milton Keynes ICB	9,142	100
Bath, North East Somerset, Swindon & Wiltshire ICB	8,907	65
Herefordshire & Worcestershire ICB	7,554	65
Dorset ICB	7,436	100
Lincolnshire ICB	7,284	65
Buckinghamshire Oxfordshire & Berkshire ICB	6,469	100
Unlocked to date	**293,191**	
Eligible Patient Population / Total	304,383 / 586,000	

Early Commercialization in EU Has Been Slow and is a Top Priority for New Leadership

National and Individual Reimbursement

- England and Wales
- Austria*
- Finland
- Denmark*
- Sweden
- Switzerland*

Pricing & Reimbursement Negotiations

- France
- Norway
- Israel
- Portugal
- Italy
- Scotland
- Netherlands
- Spain

Evaluating options for path forward in Germany

*Individual Reimbursement.

International Expansion Beyond US and Europe

- Approved
- Regulatory Preparations Underway



Continue to Negotiate Partnership Opportunities to Drive Access While Maintaining Flexibility

Additional markets underway

New markets represent 50M+ patients

Note: The company is pursuing expansion into these various additional markets and the status of regulatory and/or patent approval will vary market to market. Patient populations indicate prevalence of cardiovascular disease per Journal of the American College of Cardiology, Vol. 80 published 11/25/22
*Partnered countries.

02

FIRST QUARTER 2023 FINANCIAL RESULTS AND 2023 GUIDANCE

Tom Reilly, CFO

First Quarter 2023 Total Net Revenue Was Stable due to US Performance



U.S. Revenue Remains Stable in Dynamic Generic Market

- 1Q 2023 total net revenues were **$86 million,–5% vs Q4 '22**
- In the US, Teva 1 gm listed in Q1 but little market impact to date
- 1Q 2023 European net revenues were **$0.4 million**

Ongoing Effort to Drive Operating Expense Improvements



Key Drivers:

- Cost reductions plan to exceed $100 million
- Reduced 2023 operating expense guidance to $270M-$285M from $290-$305M
- Ongoing efforts to further reduce costs underway

Continued Focus on Controlling Costs And Maximizing Cash



First Quarter 2023
Cash Stable ~$5M*

- Cash balance at 3/31/2023 approximately $305M
- Continued progress renegotiating supply purchase agreements – process ongoing
- Expense reductions and timely EUR investments based on pricing and reimbursement decisions

*Includes one-time supply restructuring charge of $10M, cash flow positive excluding this charge

03

LOOKING AHEAD TO THE REMAINDER OF 2023

Aaron Berg, Interim President & CEO

2023: Continuing Focus on Key Priorities to Maximize Shareholder Value

2023
KEY PRIORITIES

- Accelerate commercialization in Europe
- Focus on operational efficiencies globally
- Expand internationally through regulatory approvals and partnerships
- Maximize profitability of US Business
- Continue to explore the development of FDC

BOLD AMBITIONS for AMARIN®

Leading a new paradigm in preventive cardiovascular care and growing our impact for patients globally

Vascepa®
(icosapent ethyl)

Vazkepa®
(icosapent ethyl)

THANK YOU

AMARIN®